Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803
- Citation:
- Eur J Cancer vol 47 (7) 990-996
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Comprehensive
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- Parents:
- 74
- Children:
- None
- Pharmas:
- Grants:
- U10 CA025224, U10 CA025224-33, CA-25224
- Corr. Author:
- Authors:
- D Sargent Q Shi G Yothers E Van Cutsem J Cassidy L Saltz N Wolmark B Bot A Grothey M Buyse A de Gramont
- Networks:
- Study
- Alliance-89803
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- Keywords:
- Article